Droxinostat is a chemical compound classified as a histone deacetylase (HDAC) inhibitor, which plays a significant role in the regulation of gene expression. It is primarily investigated for its potential therapeutic applications in cancer treatment and other diseases characterized by abnormal cell growth. The compound exhibits a unique mechanism of action by altering the acetylation status of histones, leading to changes in chromatin structure and gene transcription. Droxinostat is known for its ability to induce cell cycle arrest and apoptosis in cancer cells, making it a subject of interest in oncology research. Additionally, it may have implications in the treatment of neurodegenerative disorders due to its effects on neuronal survival and function. The substance is typically administered in a controlled setting, and its pharmacokinetics, safety profile, and efficacy are subjects of ongoing clinical studies. As with many HDAC inhibitors, potential side effects may include gastrointestinal disturbances and hematological changes, necessitating careful monitoring during treatment.

Droxinostat

Find at CymitQuimica all products linked to CAS 99873-43-5. Enter now to get more information

Droxinostat (NS 41080) is a selective inhibitor of HDAC, mostly for HDACs 6 and 8 with IC50 of 2.47 μM and 1.46 μM, greater than 8-fold selective against HDAC3

CAS 99873-43-5: Droxinostat

Droxinostat

Ref: TR-D689890

Droxinostat

Ref: 54-BUP11106

Droxinostat

Ref: 7W-GP4388

Droxinostat

Ref: TM-T6481

Droxinostat

Ref: IN-DA01B150